INDP (Indaptus Therapeutics) Cash-to-Debt: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INDP Indaptus Therapeutics Inc INDP
26 GF Score
Price $3.09
! 1 Warning Sign
View Full Analysis

What is Indaptus Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Indaptus Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was .

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Indaptus Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Indaptus Therapeutics's Cash-to-Debt or its related term are showing as below:

INDP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.94   Med: 161.52   Max: No Debt
Current: 1283.78

During the past 13 years, Indaptus Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.94. And the median was 161.52.

INDP's Cash-to-Debt is ranked better than
85.93% of 1393 companies
in the Biotechnology industry
Industry Median: 7.03 vs INDP: 1283.78

Indaptus Therapeutics  (NAS:INDP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Indaptus Therapeutics Cash-to-Debt Related Terms

Indaptus Therapeutics Cash-to-Debt Historical Data

* Premium members only.

The historical data trend for Indaptus Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Indaptus Therapeutics Cash-to-Debt Chart

Indaptus Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 231.10 328.38 76.33 68.76 -

Indaptus Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.94 670.69 - - -

INDP vs NRXP, TNYA, EQ: Cash-to-Debt Comparison

For the Biotechnology subindustry, Indaptus Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Indaptus Therapeutics Cash-to-Debt vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Indaptus Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Indaptus Therapeutics's Cash-to-Debt falls into.


INDP
26GF Score
Indaptus Therapeutics Inc INDP
Cash-to-Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indaptus Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Indaptus Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2025 is calculated as:

Indaptus Therapeutics had no debt (1).

Indaptus Therapeutics's Cash to Debt Ratio for the quarter that ended in Jun. 2026 is calculated as:

Indaptus Therapeutics had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indaptus Therapeutics Business Description

Address 3 Columbus Circle 15th Floor, New York, NY, USA, 10019
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
26GF Score

Get the complete analysis for INDP

Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.09
Price